Research Overview
Peptides for GH Axis & Hormone Optimization
A research overview of peptides studied in the context of growth hormone axis modulation, pituitary stimulation, and GH secretagogue activity.
The growth hormone axis regulates body composition, metabolic rate, sleep architecture, and tissue repair through pulsatile GH secretion and downstream IGF-1 signaling. Several peptide classes have been investigated for their ability to stimulate endogenous GH release through distinct receptor pathways.
What This Page Covers
This page reviews peptides studied for their effects on the GH axis, including GHRH analogs that stimulate pituitary GH release and ghrelin mimetics that amplify GH pulses through a complementary pathway. Evidence levels vary significantly, from FDA-approved compounds with Phase III data to research peptides with Phase II pharmacokinetic data only.
How These Peptides Interact With the GH Axis
Mechanism 01
GHRH Receptor Agonism
GHRH analogs bind to receptors on anterior pituitary somatotrophs, stimulating GH gene transcription and pulsatile GH secretion while preserving the physiological release pattern.
Mechanism 02
Ghrelin Receptor Activation
Ghrelin mimetics and GHRPs act on a separate GHS-R1a receptor pathway, amplifying GH pulses through a mechanism complementary to GHRH agonism. Combining both pathways produces synergistic GH release.
Mechanism 03
IGF-1 Downstream Signaling
GH secreted in response to these peptides acts on hepatic GH receptors to stimulate IGF-1 production, the primary downstream mediator of GH's anabolic and metabolic effects.
Peptides Commonly Discussed for GH Axis & Hormone Optimization
Ordered by evidence level.
CJC-1295
Human TrialsGHRH receptor agonism, DAC albumin binding for extended half-life
A GHRH analog with Phase II human data demonstrating 2-10 fold GH elevation sustained for 6-8 days via DAC albumin binding. The most pharmacokinetically characterized research GHRH analog.
Ipamorelin
Animal StudiesGHS-R1a agonism; highly selective GH secretagogue
A selective ghrelin mimetic that stimulates GH release without elevating cortisol, ACTH, or prolactin. Frequently combined with CJC-1295 for complementary GH axis stimulation.
Sermorelin
Human TrialsGHRH receptor agonism; endogenous GHRH fragment
The first 29 amino acids of endogenous GHRH, previously FDA-approved for GH deficiency in children. The most clinically validated GHRH analog with outcomes data in specific populations.
MK-677
Animal StudiesGHS-R1a agonism; oral bioavailability distinguishes it from injectable peptides
An orally bioavailable ghrelin mimetic that sustains GH and IGF-1 elevation. Unique as the only orally active compound in this category.
Quick Comparison
| Peptide | Primary Mechanism | Evidence | Research Context |
|---|---|---|---|
| CJC-1295 | GHRH receptor agonism, DAC albumin binding for extended half-life | Human Trials | Phase II human PK data; not FDA-approved; development program inactive |
| Ipamorelin | GHS-R1a agonism; highly selective GH secretagogue | Animal Studies | Limited human data; strong preclinical selectivity profile; not FDA-approved |
| Sermorelin | GHRH receptor agonism; endogenous GHRH fragment | Human Trials | Formerly FDA-approved; withdrawn for commercial reasons; human outcomes data available |
| MK-677 | GHS-R1a agonism; oral bioavailability distinguishes it from injectable peptides | Animal Studies | Phase II human data; elevates cortisol and prolactin unlike selective GHRPs; not FDA-approved |
What the Research Suggests
Best Evidence for GH Axis & Hormone Optimization
The GH secretagogue class has a well-characterized pharmacological basis. GHRH analogs and ghrelin mimetics reliably elevate GH and IGF-1 in human studies. The critical evidence gap is clinical outcomes, hormone elevation is a biomarker, not a health outcome, and controlled outcomes data for most compounds in this category is limited.
Strongest Individual Compound
Sermorelin has the most clinical validation with human outcomes data from its FDA-approval period. CJC-1295 has the strongest Phase II pharmacokinetic characterization among current research peptides.
What This Category Cannot Do
No compound in this category except tesamorelin (not listed here) has published Phase III outcomes data. GH and IGF-1 elevation does not automatically translate to body composition, performance, or anti-aging benefits in controlled trials. Long-term safety of sustained IGF-1 elevation requires consideration.
PSI Reading of the Evidence Gap
The GH secretagogue peptide class is pharmacologically well-understood but clinically undervalidated for most applications. Researchers should distinguish between hormone elevation data and clinical outcomes data, these are not equivalent.
How to Choose
Research-informed guidance for peptides studied in the context of gh axis & hormone optimization. Not a recommendation.
Strongest human pharmacokinetic data among research peptides
CJC-1295 (Human Trials, Phase II)
Most selective GH secretagogue, no cortisol or prolactin elevation
Ipamorelin (Animal Studies)
Most clinically validated GHRH analog with outcomes data
Sermorelin (Human Trials, formerly approved)
Regulatory Status
4 available through compounding.
Important Limitations
Formerly Approved
- Sermorelin, formerly FDA-approved for pediatric GH deficiency; withdrawn for commercial reasons
Research Peptides
- CJC-1295 (Phase II human data; not FDA-approved
- Ipamorelin) limited human data; not FDA-approved
- MK-677, Phase II human data; not FDA-approved
Key Safety Considerations
Sustained GH and IGF-1 elevation carries theoretical cancer risk concerns based on epidemiological data. None of these compounds are FDA-approved for hormone optimization in healthy adults. Clinical supervision is recommended.
No compound in this category (except tesamorelin) has FDA-approved clinical outcomes data.
GH and IGF-1 elevation is a pharmacological biomarker, not a proven clinical outcome.
Long-term safety of sustained IGF-1 elevation is not established and carries epidemiological cancer risk concerns.
CJC-1295 development program is inactive, reasons for non-progression are not publicly documented.
MK-677 elevates cortisol and prolactin in addition to GH, less selective than peptide GHRPs.
Ipamorelin human data is limited compared to its preclinical profile.
Explore More
Related Hubs
Who This May Apply To
Individuals researching peptides studied for growth hormone axis modulation and GH secretagogue activity.
Healthcare providers evaluating the evidence base for GHRH analogs and ghrelin mimetics.
Researchers comparing the pharmacokinetic and selectivity profiles of GH axis peptides.
Individuals evaluating the distinction between GHRH pathway and ghrelin pathway GH stimulation.